1. Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1.
- Author
-
Dans MG, Boulet C, Watson GM, Nguyen W, Dziekan JM, Evelyn C, Reaksudsan K, Mehra S, Razook Z, Geoghegan ND, Mlodzianoski MJ, Goodman CD, Ling DB, Jonsdottir TK, Tong J, Famodimu MT, Kristan M, Pollard H, Stewart LB, Brandner-Garrod L, Sutherland CJ, Delves MJ, McFadden GI, Barry AE, Crabb BS, de Koning-Ward TF, Rogers KL, Cowman AF, Tham WH, Sleebs BE, and Gilson PR
- Subjects
- Animals, Carrier Proteins metabolism, Carrier Proteins genetics, Mutation, Malaria, Falciparum parasitology, Malaria, Falciparum prevention & control, Malaria, Falciparum drug therapy, Humans, Drug Resistance genetics, Drug Resistance drug effects, Life Cycle Stages drug effects, Plasmodium falciparum drug effects, Plasmodium falciparum genetics, Plasmodium falciparum metabolism, Plasmodium falciparum growth & development, Acetamides pharmacology, Acetamides chemistry, Protozoan Proteins metabolism, Protozoan Proteins genetics, Antimalarials pharmacology, Antimalarials chemistry
- Abstract
With resistance to most antimalarials increasing, it is imperative that new drugs are developed. We previously identified an aryl acetamide compound, MMV006833 (M-833), that inhibited the ring-stage development of newly invaded merozoites. Here, we select parasites resistant to M-833 and identify mutations in the START lipid transfer protein (PF3D7_0104200, PfSTART1). Introducing PfSTART1 mutations into wildtype parasites reproduces resistance to M-833 as well as to more potent analogues. PfSTART1 binding to the analogues is validated using organic solvent-based Proteome Integral Solubility Alteration (Solvent PISA) assays. Imaging of invading merozoites shows the inhibitors prevent the development of ring-stage parasites potentially by inhibiting the expansion of the encasing parasitophorous vacuole membrane. The PfSTART1-targeting compounds also block transmission to mosquitoes and with multiple stages of the parasite's lifecycle being affected, PfSTART1 represents a drug target with a new mechanism of action., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF